SCHEMBL5757327

SCHEMBL5757327

CSc1nc2ccc(S(=O)(=O)N(Cc3ccccc3)[C@@H](C(=O)O)C(C)C)cc2s1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 7/20 0.56
MMP9 P14780 7/20 0.56
MMP8 P22894 6/20 0.56
MMP13 P45452 5/20 0.56
MMP12 P39900 1/20 0.54
ADAMTS4 O75173 1/20 0.51
PKM P14618 2/20 0.49
POLB P06746 1/20 0.44
ALDH1A1 P00352 2/20 0.44
GFER P55789 1/20 0.44
LMNA P02545 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5754370 0.91 MMP2 (0.54) MMP2MMP9MMP8MMP13MMP12
SCHEMBL5757072 0.89 MMP2 (0.52) MMP2MMP9MMP8MMP13MMP12
SCHEMBL5755994 0.87 MMP2 (0.51) MMP2MMP9MMP8MMP13MMP12
SCHEMBL5758792 0.87 MMP2 (0.59) MMP2MMP9MMP8MMP13MMP12
SCHEMBL5757620 0.87 MMP2 (0.50) MMP2MMP9MMP8MMP13MMP12
SCHEMBL5760177 0.86 MMP2 (0.49) MMP2MMP9MMP8MMP13MMP12
SCHEMBL5756061 0.86 MMP2 (0.49) MMP2MMP9MMP8MMP13MMP12
SCHEMBL5753594 0.86 MMP2 (0.49) MMP2MMP9MMP8MMP13MMP12
SCHEMBL5758963 0.84 MMP2 (0.47) MMP2MMP9MMP8MMP13MMP12
SCHEMBL5759304 0.83 MMP2 (0.56) MMP2MMP9MMP8MMP13MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 MMP2 8/4885MMP9 1/4885MMP8 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.